AB Science Revised Drug Development Plans
The company overhauled its quality management system following a multi-country clinical practice inspection.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize rigorous quality standards over financial goals in clinical trials?
AB Science has updated its development and financial calendars after undergoing a sponsor Good Clinical Practice inspection by health authorities from France, Denmark, and Greece. The inspection took place in late September 2026, prompting the firm to prioritize systemic quality improvements.
Why it matters
These changes reflect a strategic shift to ensure patient safety and data robustness across the company's clinical programs. Management is now reassessing trial protocols to prioritize scientific merit as they restructure their internal quality systems.
The review involved 5 health authority inspectors from France, Denmark, and Greece. The final inspection report remains pending until the end of 2026.
The players
AB Science
A pharmaceutical company focused on the development of kinase inhibitors like masitinib for inflammatory and neurodegenerative diseases.
The details
AB Science is implementing a comprehensive new quality management system, supported by an external audit, to oversee its research pipeline. Clinical trial protocols are being adjusted to balance financial constraints against scientific requirements. This overhaul follows a for-cause sponsor Good Clinical Practice inspection—a regulatory audit designed to verify that clinical studies comply with international standards for patient safety and data integrity.
Timeline
July 13, 2026: Initiation of quality management system overhaul.
September 21-25, 2026: Good Clinical Practice inspection conducted by three health authorities.
October 9, 2026: Scheduled publication date for the half-year financial report.
Q1 2027: Anticipated resumption of the phase 1 study in acute myeloid leukemia.
Q4 2027: Anticipated resumption of the phase 3 study in amyotrophic lateral sclerosis.
The Tech Race
The development plan update highlights the ongoing pressure on biotech firms to meet stringent Good Clinical Practice standards while maintaining clinical trial momentum. This move follows a period of organizational restructuring as the company seeks to align its masitinib program with robust regulatory benchmarks.
Patients and stakeholders should note that studies in acute myeloid leukemia and amyotrophic lateral sclerosis remain paused until 2027. Clinical trial timelines for the masitinib program in sickle cell disease are similarly shifted as the firm prioritizes its new quality management framework.
The takeaway
The company has prioritized systemic quality over previous trial schedules to ensure long-term data integrity. Investors and researchers should monitor the publication of the final inspection report due by the end of 2026 to gauge the future viability of the masitinib program.
What happens next
The company expects to publish its half-year financial report on October 9, 2026, and anticipates receiving the final inspection report by the end of 2026.
Further reading
For more on industry regulatory standards, visit Biotech.
Live Poll
Do you trust pharmaceutical companies to prioritize rigorous quality standards over financial goals in clinical trials?
